The FDA approved rituximab-abbs (Truxima, Celltrion/Teva), the first biosimilar to rituximab (Rituxan, Biogen/Genentech), for use in the treatment of adults with CD20-positive B-cell non-Hodgkin lymphoma (NHL) as a single agent or in combination with chemotherapy.The agency said rituximab-abbs was approved as a biosimilar, not as an interchangeable product.
DECEMBER 1, 2018